Premium
Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease
Author(s) -
Gustavsson Anders,
Green Colin,
Jones Roy W.,
Förstl Hans,
Simsek Deniz,
Reydet de Vulpillieres Frederic,
Luthman Stefanie,
Adlard Nicholas,
Bhattacharyya Subrata,
Wimo Anders
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.12.005
Subject(s) - institutionalisation , disease , relevance (law) , warrant , scale (ratio) , risk analysis (engineering) , medicine , management science , public economics , intensive care medicine , actuarial science , psychology , political science , business , economics , psychiatry , geography , pathology , cartography , finance , law
Available data and models for the health‐economic evaluation of treatment in Alzheimer's disease (AD) have limitations causing uncertainty to decision makers. Forthcoming treatment strategies in preclinical or early AD warrant an update on the challenges associated with their economic evaluation. The perspectives of the co‐authors were complemented with a targeted review of literature discussing methodological issues and data gaps in AD health‐economic modelling. The methods and data available to translate treatment efficacy in early disease into long‐term outcomes of relevance to policy makers and payers are limited. Current long‐term large‐scale data accurately representing the continuous, multifaceted, and heterogeneous disease process are missing. The potential effect of disease‐modifying treatment on key long‐term outcomes such as institutionalization and death is uncertain but may have great effect on cost‐effectiveness. Future research should give priority to collaborative efforts to access better data on the natural progression of AD and its association with key long‐term outcomes.